Head to Head Analysis: InflaRx (IFRX) vs. Array BioPharma (ARRY)

InflaRx (NASDAQ: IFRX) and Array BioPharma (NASDAQ:ARRY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Profitability

This table compares InflaRx and Array BioPharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InflaRx N/A N/A N/A
Array BioPharma -72.33% -96.65% -31.97%

Analyst Recommendations

This is a summary of recent recommendations for InflaRx and Array BioPharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InflaRx 0 0 4 0 3.00
Array BioPharma 0 0 8 0 3.00

InflaRx currently has a consensus price target of $34.25, indicating a potential downside of 0.41%. Array BioPharma has a consensus price target of $18.38, indicating a potential upside of 16.67%. Given Array BioPharma’s higher possible upside, analysts clearly believe Array BioPharma is more favorable than InflaRx.

Institutional and Insider Ownership

42.8% of InflaRx shares are owned by institutional investors. Comparatively, 96.9% of Array BioPharma shares are owned by institutional investors. 3.2% of Array BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares InflaRx and Array BioPharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InflaRx N/A N/A -$27.39 million N/A N/A
Array BioPharma $150.85 million 21.99 -$116.81 million ($0.72) -21.88

InflaRx has higher earnings, but lower revenue than Array BioPharma.

Summary

Array BioPharma beats InflaRx on 5 of the 9 factors compared between the two stocks.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

About Array BioPharma

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply